6 O
ADVERSE O
REACTIONS O
The O
following O
adverse O
reactions O
are O
discussed O
in O
more O
detail O
in O
other O
sections O
of O
the O
labeling O
: O
* O
Increased O
Mortality B-NonOSE_AE
in O
Elderly O
Patients O
with O
Dementia B-Not_AE_Candidate
- I-Not_AE_Candidate
Related I-Not_AE_Candidate
Psychosis I-Not_AE_Candidate
[ O
see O
Boxed O
Warning O
and O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
* O
Suicidal B-OSE_Labeled_AE
Thoughts I-OSE_Labeled_AE
and O
Behaviors O
[ O
see O
Boxed O
Warning O
and O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
* O
Cerebrovascular B-NonOSE_AE
Adverse I-NonOSE_AE
Reactions I-NonOSE_AE
, O
Including O
Stroke B-NonOSE_AE
, O
in O
Elderly O
Patients O
with O
Dementia B-Not_AE_Candidate
- I-Not_AE_Candidate
related I-Not_AE_Candidate
Psychosis I-Not_AE_Candidate
[ O
see O
Warnings O
and O
Precautions O
( O
5.23 O
) O
] O
* O
Neuroleptic B-OSE_Labeled_AE
Malignant I-OSE_Labeled_AE
Syndrome I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.4 O
) O
] O
* O
Tardive B-OSE_Labeled_AE
Dyskinesia I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.5 O
) O
] O
* O
Metabolic B-OSE_Labeled_AE
Changes I-OSE_Labeled_AE
( O
Hyperglycemia B-OSE_Labeled_AE
and O
Diabetes B-Not_AE_Candidate
Mellitus I-Not_AE_Candidate
, O
Dyslipidemia B-OSE_Labeled_AE
, O
and O
Weight B-OSE_Labeled_AE
Gain I-OSE_Labeled_AE
) O
[ O
see O
Warnings O
and O
Precautions O
( O
5.6 O
) O
] O
* O
Hyperprolactinemia B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.7 O
) O
] O
* O
Leukopenia B-OSE_Labeled_AE
, O
Neutropenia B-OSE_Labeled_AE
, O
and O
Agranulocytosis B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.8 O
) O
] O
* O
Orthostatic B-OSE_Labeled_AE
Hypotension I-OSE_Labeled_AE
and O
Syncope B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.9 O
) O
] O
* O
Seizures B-NonOSE_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.10 O
) O
] O
* O
Potential O
for O
Cognitive B-OSE_Labeled_AE
and O
Motor O
Impairment I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.11 O
) O
] O
* O
Body B-OSE_Labeled_AE
Temperature I-OSE_Labeled_AE
Dysregulation I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.12 O
) O
] O
* O
Suicide B-NonOSE_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.13 O
) O
] O
* O
Activation B-OSE_Labeled_AE
of I-OSE_Labeled_AE
Mania/ O
Hypomania I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.14 O
) O
] O
* O
Dysphagia B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.15 O
) O
] O
* O
Neurological B-OSE_Labeled_AE
Adverse I-OSE_Labeled_AE
Reactions I-OSE_Labeled_AE
in O
Patients O
with O
Parkinson B-Not_AE_Candidate
' I-Not_AE_Candidate
s I-Not_AE_Candidate
Disease I-Not_AE_Candidate
or O
Dementia B-Not_AE_Candidate
with I-Not_AE_Candidate
Lewy I-Not_AE_Candidate
Bodies I-Not_AE_Candidate
[ O
see O
Warnings O
and O
Precautions O
( O
5.16 O
) O
] O
EXCERPT O
: O
Commonly O
observed O
adverse O
reactions O
( O
incidence O
> O
= O
5 O
% O
and O
at O
least O
twice O
the O
rate O
for O
placebo O
) O
were O
( O
6.1 O
) O
: O
* O
Schizophrenia O
: O
somnolence O
, O
akathisia O
, O
extrapyramidal O
symptoms O
, O
and O
nausea O
* O
Bipolar O
depression O
: O
akathisia O
, O
extrapyramidal O
symptoms O
, O
and O
somnolence O
To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
Sunovion O
Pharmaceuticals O
Inc O
. O
at O
1-877-737-7226 O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
. O

6.1 O
Clinical O
Trials O
Experience O
Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
clinical O
trials O
of O
a O
drug O
can O
not O
be O
directly O
compared O
to O
rates O
in O
the O
clinical O
trials O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
clinical O
practice O
. O

The O
information O
below O
is O
derived O
from O
an O
integrated O
clinical O
study O
database O
for O
LATUDA O
consisting O
of O
3799 O
patients O
exposed O
to O
one O
or O
more O
doses O
of O
LATUDA O
for O
the O
treatment O
of O
schizophrenia B-Not_AE_Candidate
and O
bipolar B-Not_AE_Candidate
depression I-Not_AE_Candidate
in O
placebo-controlled O
studies O
. O

This O
experience O
corresponds O
with O
a O
total O
experience O
of O
1250.9 O
patient-years O
. O

A O
total O
of O
1106 O
LATUDA-treated O
patients O
had O
at O
least O
24 O
weeks O
and O
371 O
LATUDA-treated O
patients O
had O
at O
least O
52 O
weeks O
of O
exposure O
. O

Adverse O
events O
during O
exposure O
to O
study O
treatment O
were O
obtained O
by O
general O
inquiry O
and O
voluntarily O
reported O
adverse O
experiences O
, O
as O
well O
as O
results O
from O
physical O
examinations O
, O
vital O
signs O
, O
ECGs O
, O
weights O
and O
laboratory O
investigations O
. O

Adverse O
experiences O
were O
recorded O
by O
clinical O
investigators O
using O
their O
own O
terminology O
. O

In O
order O
to O
provide O
a O
meaningful O
estimate O
of O
the O
proportion O
of O
individuals O
experiencing O
adverse O
events O
, O
events O
were O
grouped O
in O
standardized O
categories O
using O
MedDRA O
terminology O
. O

Schizophrenia O
The O
following O
findings O
are O
based O
on O
the O
short-term O
, O
placebo-controlled O
premarketing O
studies O
for O
schizophrenia B-Not_AE_Candidate
in O
which O
LATUDA O
was O
administered O
at O
daily O
doses O
ranging O
from O
20 O
to O
160 O
mg O
( O
n=1508 O
) O
. O

Commonly O
Observed O
Adverse O
Reactions O
: O
The O
most O
common O
adverse O
reactions O
( O
incidence O
> O
= O
5 O
% O
and O
at O
least O
twice O
the O
rate O
of O
placebo O
) O
in O
patients O
treated O
with O
LATUDA O
were O
somnolence B-OSE_Labeled_AE
, O
akathisia B-OSE_Labeled_AE
, O
extrapyramidal B-OSE_Labeled_AE
symptoms I-OSE_Labeled_AE
, O
and O
nausea B-OSE_Labeled_AE
. O

Adverse O
Reactions O
Associated O
with O
Discontinuation O
of O
Treatment O
: O
A O
total O
of O
9.5 O
% O
( O
143/1508 O
) O
LATUDA-treated O
patients O
and O
9.3 O
% O
( O
66/708 O
) O
of O
placebo-treated O
patients O
discontinued O
due O
to O
adverse O
reactions O
. O

There O
were O
no O
adverse O
reactions O
associated O
with O
discontinuation O
in O
subjects O
treated O
with O
LATUDA O
that O
were O
at O
least O
2 O
% O
and O
at O
least O
twice O
the O
placebo O
rate O
. O

Adverse O
Reactions O
Occurring O
at O
an O
Incidence O
of O
2 O
% O
or O
More O
in O
LATUDA-Treated O
Patients O
: O
Adverse O
reactions O
associated O
with O
the O
use O
of O
LATUDA O
( O
incidence O
of O
2 O
% O
or O
greater O
, O
rounded O
to O
the O
nearest O
percent O
and O
LATUDA O
incidence O
greater O
than O
placebo O
) O
that O
occurred O
during O
acute O
therapy O
( O
up O
to O
6 O
weeks O
in O
patients O
with O
schizophrenia O
) O
are O
shown O
in O
Table O
15 O
. O

Table O
15 O
: O
Adverse O
Reactions O
in O
2 O
% O
or O
More O
of O
LATUDA-Treated O
Patients O
and O
That O
Occurred O
at O
Greater O
Incidence O
than O
in O
the O
Placebo-Treated O
Patients O
in O
Short-term O
Schizophrenia O
Studies O
Note O
: O
Figures O
rounded O
to O
the O
nearest O
integer O
* O
Somnolence B-OSE_Labeled_AE
includes O
adverse O
event O
terms O
: O
hypersomnia B-OSE_Labeled_AE
, O
hypersomnolence B-OSE_Labeled_AE
, O
sedation B-OSE_Labeled_AE
, O
and O
somnolence B-OSE_Labeled_AE
** O
Extrapyramidal B-OSE_Labeled_AE
symptoms I-OSE_Labeled_AE
includes O
adverse O
event O
terms O
: O
bradykinesia B-OSE_Labeled_AE
, O
cogwheel B-OSE_Labeled_AE
rigidity I-OSE_Labeled_AE
, O
drooling B-OSE_Labeled_AE
, O
dystonia B-OSE_Labeled_AE
, O
extrapyramidal B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
, O
hypokinesia B-OSE_Labeled_AE
, O
muscle B-OSE_Labeled_AE
rigidity I-OSE_Labeled_AE
, O
oculogyric B-OSE_Labeled_AE
crisis I-OSE_Labeled_AE
, O
oromandibular B-OSE_Labeled_AE
dystonia I-OSE_Labeled_AE
, O
parkinsonism B-OSE_Labeled_AE
, O
psychomotor B-OSE_Labeled_AE
retardation I-OSE_Labeled_AE
, O
tongue B-OSE_Labeled_AE
spasm I-OSE_Labeled_AE
, O
torticollis B-OSE_Labeled_AE
, O
tremor B-OSE_Labeled_AE
, O
and O
trismus B-OSE_Labeled_AE
Percentage O
of O
Patients O
Reporting O
Reaction O
LATUDA O
Body O
System O
or O
Organ O
Class O
Placebo O
( O
N=708 O
) O
( O
% O
) O
20 O
mg/day O
( O
N=71 O
) O
( O
% O
) O
40 O
mg/day O
( O
N=487 O
) O
( O
% O
) O
80 O
mg/day O
( O
N=538 O
) O
( O
% O
) O
120 O
mg/day O
( O
N=291 O
) O
( O
% O
) O
160 O
mg/day O
( O
N=121 O
) O
( O
% O
) O
All O
LATUDA O
( O
N=1508 O
) O
( O
% O
) O
Gastrointestinal B-NonOSE_AE
Disorders I-NonOSE_AE
Nausea B-OSE_Labeled_AE
5 O
11 O
10 O
9 O
13 O
7 O
10 O
Vomiting B-OSE_Labeled_AE
6 O
7 O
6 O
9 O
9 O
7 O
8 O
Dyspepsia B-OSE_Labeled_AE
5 O
11 O
6 O
5 O
8 O
6 O
6 O
Salivary B-OSE_Labeled_AE
Hypersecretion I-OSE_Labeled_AE
< O
1 O
1 O
1 O
2 O
4 O
2 O
2 O
Musculoskeletal B-NonOSE_AE
and I-NonOSE_AE
Connective I-NonOSE_AE
Tissue I-NonOSE_AE
Disorders I-NonOSE_AE
Back B-OSE_Labeled_AE
Pain I-OSE_Labeled_AE
2 O
0 O
4 O
3 O
4 O
0 O
3 O
Nervous B-NonOSE_AE
System I-NonOSE_AE
Disorders I-NonOSE_AE
Somnolence B-OSE_Labeled_AE
* O
7 O
15 O
16 O
15 O
26 O
8 O
17 O
Akathisia B-OSE_Labeled_AE
3 O
6 O
11 O
12 O
22 O
7 O
13 O
Extrapyramidal B-OSE_Labeled_AE
Disorder I-OSE_Labeled_AE
** O
6 O
6 O
11 O
12 O
22 O
13 O
14 O
Dizziness B-OSE_Labeled_AE
2 O
6 O
4 O
4 O
5 O
6 O
4 O
Psychiatric B-NonOSE_AE
Disorders I-NonOSE_AE
Insomnia B-OSE_Labeled_AE
8 O
8 O
10 O
11 O
9 O
7 O
10 O
Agitation B-OSE_Labeled_AE
4 O
10 O
7 O
3 O
6 O
5 O
5 O
Anxiety B-OSE_Labeled_AE
4 O
3 O
6 O
4 O
7 O
3 O
5 O
Restlessness B-OSE_Labeled_AE
1 O
1 O
3 O
1 O
3 O
2 O
2 O
Dose-Related O
Adverse O
Reactions O
in O
the O
Schizophrenia O
Studies O
Akathisia B-OSE_Labeled_AE
and O
extrapyramidal B-OSE_Labeled_AE
symptoms I-OSE_Labeled_AE
were O
dose-related O
. O

The O
frequency O
of O
akathisia B-OSE_Labeled_AE
increased O
with O
dose O
up O
to O
120 O
mg/day O
( O
5.6 O
% O
for O
LATUDA O
20 O
mg O
, O
10.7 O
% O
for O
LATUDA O
40 O
mg O
, O
12.3 O
% O
for O
LATUDA O
80 O
mg O
, O
and O
22.0 O
% O
for O
LATUDA O
120 O
mg O
) O
. O

Akathisia B-OSE_Labeled_AE
was O
reported O
by O
7.4 O
% O
( O
9/121 O
) O
of O
patients O
receiving O
160 O
mg/day O
. O

Akathisia B-NonOSE_AE
occurred O
in O
3.0 O
% O
of O
subjects O
receiving O
placebo O
. O

The O
frequency O
of O
extrapyramidal B-OSE_Labeled_AE
symptoms I-OSE_Labeled_AE
increased O
with O
dose O
up O
to O
120 O
mg/day O
( O
5.6 O
% O
for O
LATUDA O
20 O
mg O
, O
11.5 O
% O
for O
LATUDA O
40 O
mg O
, O
11.9 O
% O
for O
LATUDA O
80 O
mg O
, O
and O
22.0 O
% O
for O
LATUDA O
120 O
mg O
) O
. O

Bipolar O
Depression O
( O
Monotherapy O
) O
The O
following O
findings O
are O
based O
on O
the O
short-term O
, O
placebo-controlled O
premarketing O
study O
for O
bipolar B-Not_AE_Candidate
depression I-Not_AE_Candidate
in O
which O
LATUDA O
was O
administered O
at O
daily O
doses O
ranging O
from O
20 O
to O
120 O
mg O
( O
n=331 O
) O
. O

Commonly O
Observed O
Adverse O
Reactions O
: O
The O
most O
common O
adverse O
reactions O
( O
incidence O
> O
= O
5 O
% O
, O
in O
either O
dose O
group O
, O
and O
at O
least O
twice O
the O
rate O
of O
placebo O
) O
in O
patients O
treated O
with O
LATUDA O
were O
akathisia B-OSE_Labeled_AE
, O
extrapyramidal B-OSE_Labeled_AE
symptoms I-OSE_Labeled_AE
, O
somnolence B-OSE_Labeled_AE
, O
nausea B-OSE_Labeled_AE
, O
vomiting B-OSE_Labeled_AE
, O
diarrhea B-OSE_Labeled_AE
, O
and O
anxiety B-OSE_Labeled_AE
. O

Adverse O
Reactions O
Associated O
with O
Discontinuation O
of O
Treatment O
: O
A O
total O
of O
6.0 O
% O
( O
20/331 O
) O
LATUDA-treated O
patients O
and O
5.4 O
% O
( O
9/168 O
) O
of O
placebo-treated O
patients O
discontinued O
due O
to O
adverse O
reactions O
. O

There O
were O
no O
adverse O
reactions O
associated O
with O
discontinuation O
in O
subjects O
treated O
with O
LATUDA O
that O
were O
at O
least O
2 O
% O
and O
at O
least O
twice O
the O
placebo O
rate O
. O

Adverse O
Reactions O
Occurring O
at O
an O
Incidence O
of O
2 O
% O
or O
More O
in O
LATUDA-Treated O
Patients O
: O
Adverse O
reactions O
associated O
with O
the O
use O
of O
LATUDA O
( O
incidence O
of O
2 O
% O
or O
greater O
, O
rounded O
to O
the O
nearest O
percent O
and O
LATUDA O
incidence O
greater O
than O
placebo O
) O
that O
occurred O
during O
acute O
therapy O
( O
up O
to O
6 O
weeks O
in O
patients O
with O
bipolar B-Not_AE_Candidate
depression I-Not_AE_Candidate
) O
are O
shown O
in O
Table O
16 O
. O

Table O
16 O
: O
Adverse O
Reactions O
in O
2 O
% O
or O
More O
of O
LATUDA-Treated O
Patients O
and O
That O
Occurred O
at O
Greater O
Incidence O
than O
in O
the O
Placebo-Treated O
Patients O
in O
a O
Short-term O
Monotherapy O
Bipolar B-Not_AE_Candidate
Depression I-Not_AE_Candidate
Study O
Note O
: O
Figures O
rounded O
to O
the O
nearest O
integer O
* O
Extrapyramidal B-OSE_Labeled_AE
symptoms I-OSE_Labeled_AE
includes O
adverse O
event O
terms O
: O
bradykinesia B-OSE_Labeled_AE
, O
cogwheel B-OSE_Labeled_AE
rigidity I-OSE_Labeled_AE
, O
drooling B-OSE_Labeled_AE
, O
dystonia B-OSE_Labeled_AE
, O
extrapyramidal B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
, O
glabellar B-OSE_Labeled_AE
reflex I-OSE_Labeled_AE
abnormal I-OSE_Labeled_AE
, O
hypokinesia B-OSE_Labeled_AE
, O
muscle B-OSE_Labeled_AE
rigidity I-OSE_Labeled_AE
, O
oculogyric B-OSE_Labeled_AE
crisis I-OSE_Labeled_AE
, O
oromandibular B-OSE_Labeled_AE
dystonia I-OSE_Labeled_AE
, O
parkinsonism B-OSE_Labeled_AE
, O
psychomotor B-OSE_Labeled_AE
retardation I-OSE_Labeled_AE
, O
tongue B-OSE_Labeled_AE
spasm I-OSE_Labeled_AE
, O
torticollis B-OSE_Labeled_AE
, O
tremor B-OSE_Labeled_AE
, O
and O
trismus B-OSE_Labeled_AE
** O
Somnolence B-OSE_Labeled_AE
includes O
adverse O
event O
terms O
: O
hypersomnia B-OSE_Labeled_AE
, O
hypersomnolence B-OSE_Labeled_AE
, O
sedation B-OSE_Labeled_AE
, O
and O
somnolence B-OSE_Labeled_AE
Percentage O
of O
Patients O
Reporting O
Reaction O
Body O
System O
or O
Organ O
Class O
Dictionary-derived O
Term O
Placebo O
( O
N=168 O
) O
( O
% O
) O
LATUDA O
20-60 O
mg/day O
( O
N=164 O
) O
( O
% O
) O
LATUDA O
80-120 O
mg/day O
( O
N=167 O
) O
( O
% O
) O
All O
LATUDA O
( O
N=331 O
) O
( O
% O
) O
Gastrointestinal B-NonOSE_AE
Disorders I-NonOSE_AE
Nausea B-OSE_Labeled_AE
8 O
10 O
17 O
14 O
Dry B-OSE_Labeled_AE
Mouth I-OSE_Labeled_AE
4 O
6 O
4 O
5 O
Vomiting B-OSE_Labeled_AE
2 O
2 O
6 O
4 O
Diarrhea B-OSE_Labeled_AE
2 O
5 O
3 O
4 O
Infections B-NonOSE_AE
and I-NonOSE_AE
Infestations I-NonOSE_AE
Nasopharyngitis B-OSE_Labeled_AE
1 O
4 O
4 O
4 O
Influenza B-OSE_Labeled_AE
1 O
< O
1 O
2 O
2 O
Urinary B-OSE_Labeled_AE
Tract I-OSE_Labeled_AE
Infection I-OSE_Labeled_AE
< O
1 O
2 O
1 O
2 O
Musculoskeletal B-NonOSE_AE
and I-NonOSE_AE
Connective I-NonOSE_AE
Tissue I-NonOSE_AE
Disorders I-NonOSE_AE
Back B-OSE_Labeled_AE
Pain I-OSE_Labeled_AE
< O
1 O
3 O
< O
1 O
2 O
Nervous B-NonOSE_AE
System I-NonOSE_AE
Disorders I-NonOSE_AE
Extrapyramidal B-OSE_Labeled_AE
Symptoms I-OSE_Labeled_AE
* O
2 O
5 O
9 O
7 O
Akathisia B-OSE_Labeled_AE
2 O
8 O
11 O
9 O
Somnolence B-OSE_Labeled_AE
** O
7 O
7 O
14 O
11 O
Psychiatric B-NonOSE_AE
Disorders I-NonOSE_AE
Anxiety B-OSE_Labeled_AE
1 O
4 O
5 O
4 O
Dose-Related O
Adverse O
Reactions O
in O
the O
Monotherapy O
Study O
: O
In O
the O
short-term O
, O
placebo-controlled O
study O
( O
involving O
lower O
and O
higher O
LATUDA O
dose O
ranges O
) O
[ O
see O
Clinical O
Studies O
( O
14.2 O
) O
] O
the O
adverse O
reactions O
that O
occurred O
with O
a O
greater O
than O
5 O
% O
incidence O
in O
the O
patients O
treated O
with O
LATUDA O
in O
any O
dose O
group O
and O
greater O
than O
placebo O
in O
both O
groups O
were O
nausea B-OSE_Labeled_AE
( O
10.4 O
% O
, O
17.4 O
% O
) O
, O
somnolence B-OSE_Labeled_AE
( O
7.3 O
% O
, O
13.8 O
% O
) O
, O
akathisia B-OSE_Labeled_AE
( O
7.9 O
% O
, O
10.8 O
% O
) O
, O
and O
extrapyramidal B-OSE_Labeled_AE
symptoms I-OSE_Labeled_AE
( O
4.9 O
% O
, O
9.0 O
% O
) O
for O
LATUDA O
20 O
to O
60 O
mg/day O
and O
LATUDA O
80 O
to O
120 O
mg/day O
, O
respectively O
. O

Bipolar O
Depression O
Adjunctive O
Therapy O
with O
Lithium O
or O
Valproate O
The O
following O
findings O
are O
based O
on O
two O
short-term O
, O
placebo-controlled O
premarketing O
studies O
for O
bipolar B-Not_AE_Candidate
depression I-Not_AE_Candidate
in O
which O
LATUDA O
was O
administered O
at O
daily O
doses O
ranging O
from O
20 O
to O
120 O
mg O
as O
adjunctive O
therapy O
with O
lithium O
or O
valproate O
( O
n=360 O
) O
. O

Commonly O
Observed O
Adverse O
Reactions O
: O
The O
most O
common O
adverse O
reactions O
( O
incidence O
> O
= O
5 O
% O
and O
at O
least O
twice O
the O
rate O
of O
placebo O
) O
in O
subjects O
treated O
with O
LATUDA O
were O
akathisia B-OSE_Labeled_AE
and O
somnolence B-OSE_Labeled_AE
. O

Adverse O
Reactions O
Associated O
with O
Discontinuation O
of O
Treatment O
: O
A O
total O
of O
5.8 O
% O
( O
21/360 O
) O
LATUDA-treated O
patients O
and O
4.8 O
% O
( O
16/334 O
) O
of O
placebo-treated O
patients O
discontinued O
due O
to O
adverse O
reactions O
. O

There O
were O
no O
adverse O
reactions O
associated O
with O
discontinuation O
in O
subjects O
treated O
with O
LATUDA O
that O
were O
at O
least O
2 O
% O
and O
at O
least O
twice O
the O
placebo O
rate O
. O

Adverse O
Reactions O
Occurring O
at O
an O
Incidence O
of O
2 O
% O
or O
More O
in O
LATUDA-Treated O
Patients O
: O
Adverse O
reactions O
associated O
with O
the O
use O
of O
LATUDA O
( O
incidence O
of O
2 O
% O
or O
greater O
, O
rounded O
to O
the O
nearest O
percent O
and O
LATUDA O
incidence O
greater O
than O
placebo O
) O
that O
occurred O
during O
acute O
therapy O
( O
up O
to O
6 O
weeks O
in O
patients O
with O
bipolar B-Not_AE_Candidate
depression I-Not_AE_Candidate
) O
are O
shown O
in O
Table O
17 O
. O

Table O
17 O
: O
Adverse O
Reactions O
in O
2 O
% O
or O
More O
of O
LATUDA-Treated O
Patients O
and O
That O
Occurred O
at O
Greater O
Incidence O
than O
in O
the O
Placebo-Treated O
Patients O
in O
the O
Short-term O
Adjunctive O
Therapy O
Bipolar O
Depression O
Studies O
Note O
: O
Figures O
rounded O
to O
the O
nearest O
integer O
* O
Extrapyramidal B-OSE_Labeled_AE
symptoms I-OSE_Labeled_AE
includes O
adverse O
event O
terms O
: O
bradykinesia B-OSE_Labeled_AE
, O
cogwheel B-OSE_Labeled_AE
rigidity I-OSE_Labeled_AE
, O
drooling B-OSE_Labeled_AE
, O
dystonia B-OSE_Labeled_AE
, O
extrapyramidal B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
, O
glabellar B-OSE_Labeled_AE
reflex I-OSE_Labeled_AE
abnormal I-OSE_Labeled_AE
, O
hypokinesia B-OSE_Labeled_AE
, O
muscle B-OSE_Labeled_AE
rigidity I-OSE_Labeled_AE
, O
oculogyric B-OSE_Labeled_AE
crisis I-OSE_Labeled_AE
, O
oromandibular B-OSE_Labeled_AE
dystonia I-OSE_Labeled_AE
, O
parkinsonism B-OSE_Labeled_AE
, O
psychomotor B-OSE_Labeled_AE
retardation I-OSE_Labeled_AE
, O
tongue B-OSE_Labeled_AE
spasm I-OSE_Labeled_AE
, O
torticollis B-OSE_Labeled_AE
, O
tremor B-OSE_Labeled_AE
, O
and O
trismus B-OSE_Labeled_AE
** O
Somnolence B-OSE_Labeled_AE
includes O
adverse O
event O
terms O
: O
hypersomnia B-OSE_Labeled_AE
, O
hypersomnolence B-OSE_Labeled_AE
, O
sedation B-OSE_Labeled_AE
, O
and O
somnolence B-OSE_Labeled_AE
Percentage O
of O
Patients O
Reporting O
Reaction O
Body O
System O
or O
Organ O
Class O
Dictionary-derived O
Term O
Placebo O
( O
N=334 O
) O
( O
% O
) O
LATUDA O
20 O
to O
120 O
mg/day O
( O
N=360 O
) O
( O
% O
) O
Gastrointestinal B-NonOSE_AE
Disorders I-NonOSE_AE
Nausea B-OSE_Labeled_AE
10 O
14 O
Vomiting B-OSE_Labeled_AE
1 O
4 O
General B-NonOSE_AE
Disorders I-NonOSE_AE
Fatigue B-OSE_Labeled_AE
1 O
3 O
Infections B-NonOSE_AE
and I-NonOSE_AE
Infestations I-NonOSE_AE
Nasopharyngitis B-OSE_Labeled_AE
2 O
4 O
Investigations B-NonOSE_AE
Weight B-OSE_Labeled_AE
Increased I-OSE_Labeled_AE
< O
1 O
3 O
Metabolism B-NonOSE_AE
and I-NonOSE_AE
Nutrition I-NonOSE_AE
Disorders I-NonOSE_AE
Increased B-OSE_Labeled_AE
Appetite I-OSE_Labeled_AE
1 O
3 O
Nervous B-NonOSE_AE
System I-NonOSE_AE
Disorders I-NonOSE_AE
Extrapyramidal B-OSE_Labeled_AE
Symptoms I-OSE_Labeled_AE
* O
9 O
14 O
Somnolence B-OSE_Labeled_AE
** O
5 O
11 O
Akathisia B-OSE_Labeled_AE
5 O
11 O
Psychiatric B-NonOSE_AE
Disorders I-NonOSE_AE
Restlessness B-OSE_Labeled_AE
< O
1 O
4 O
Extrapyramidal O
Symptoms O
Schizophrenia O
In O
the O
short-term O
, O
placebo-controlled O
schizophrenia B-Not_AE_Candidate
studies O
, O
for O
LATUDA-treated O
patients O
, O
the O
incidence O
of O
reported O
events O
related O
to O
extrapyramidal B-OSE_Labeled_AE
symptoms I-OSE_Labeled_AE
( I-OSE_Labeled_AE
EPS I-OSE_Labeled_AE
) O
, O
excluding O
akathisia B-NonOSE_AE
and O
restlessness B-NonOSE_AE
, O
was O
13.5 O
% O
versus O
5.8 O
% O
for O
placebo-treated O
patients O
. O

The O
incidence O
of O
akathisia B-OSE_Labeled_AE
for O
LATUDA-treated O
patients O
was O
12.9 O
% O
versus O
3.0 O
% O
for O
placebo-treated O
patients O
. O

Incidence O
of O
EPS B-OSE_Labeled_AE
by O
dose O
is O
provided O
in O
Table O
18 O
. O

Table O
18 O
: O
Incidence O
of O
EPS O
Compared O
to O
Placebo O
in O
Schizophrenia O
Studies O
Note O
: O
Figures O
rounded O
to O
the O
nearest O
integer O
* O
Dystonia B-OSE_Labeled_AE
includes O
adverse O
event O
terms O
: O
dystonia B-OSE_Labeled_AE
, O
oculogyric B-OSE_Labeled_AE
crisis I-OSE_Labeled_AE
, O
oromandibular B-OSE_Labeled_AE
dystonia I-OSE_Labeled_AE
, O
tongue B-OSE_Labeled_AE
spasm I-OSE_Labeled_AE
, O
torticollis B-OSE_Labeled_AE
, O
and O
trismus B-OSE_Labeled_AE
** O
Parkinsonism B-OSE_Labeled_AE
includes O
adverse O
event O
terms O
: O
bradykinesia B-OSE_Labeled_AE
, O
cogwheel B-OSE_Labeled_AE
rigidity I-OSE_Labeled_AE
, O
drooling B-OSE_Labeled_AE
, O
extrapyramidal B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
, O
hypokinesia B-OSE_Labeled_AE
, O
muscle B-OSE_Labeled_AE
rigidity I-OSE_Labeled_AE
, O
parkinsonism B-OSE_Labeled_AE
, O
psychomotor B-OSE_Labeled_AE
retardation I-OSE_Labeled_AE
, O
and O
tremor B-OSE_Labeled_AE
LATUDA O
Adverse O
Event O
Term O
Placebo O
( O
N=708 O
) O
( O
% O
) O
20 O
mg/day O
( O
N=71 O
) O
( O
% O
) O
40 O
mg/day O
( O
N=487 O
) O
( O
% O
) O
80 O
mg/day O
( O
N=538 O
) O
( O
% O
) O
120 O
mg/day O
( O
N=291 O
) O
( O
% O
) O
160 O
mg/day O
( O
N=121 O
) O
( O
% O
) O
All O
EPS B-OSE_Labeled_AE
events O
9 O
10 O
21 O
23 O
39 O
20 O
All O
EPS B-OSE_Labeled_AE
events O
, O
excluding O
Akathisia B-NonOSE_AE
/ O
Restlessness B-NonOSE_AE
6 O
6 O
11 O
12 O
22 O
13 O
Akathisia B-OSE_Labeled_AE
3 O
6 O
11 O
12 O
22 O
7 O
Dystonia B-OSE_Labeled_AE
* O
< O
1 O
0 O
4 O
5 O
7 O
2 O
Parkinsonism B-OSE_Labeled_AE
** O
5 O
6 O
9 O
8 O
17 O
11 O
Restlessness B-OSE_Labeled_AE
1 O
1 O
3 O
1 O
3 O
2 O
Bipolar O
Depression O
Monotherapy O
In O
the O
short-term O
, O
placebo-controlled O
monotherapy O
bipolar B-Not_AE_Candidate
depression I-Not_AE_Candidate
study O
, O
for O
LATUDA-treated O
patients O
, O
the O
incidence O
of O
reported O
events O
related O
to O
EPS B-OSE_Labeled_AE
, O
excluding O
akathisia B-NonOSE_AE
and O
restlessness B-NonOSE_AE
was O
6.9 O
% O
versus O
2.4 O
% O
for O
placebo-treated O
patients O
. O

The O
incidence O
of O
akathisia B-NonOSE_AE
for O
LATUDA-treated O
patients O
was O
9.4 O
% O
versus O
2.4 O
% O
for O
placebo-treated O
patients O
. O

Incidence O
of O
EPS B-OSE_Labeled_AE
by O
dose O
groups O
is O
provided O
in O
Table O
19 O
. O

Table O
19 O
: O
Incidence O
of O
EPS O
Compared O
to O
Placebo O
in O
the O
Monotherapy O
Bipolar O
Depression O
Study O
LATUDA O
Adverse O
Event O
Term O
Placebo O
( O
N=168 O
) O
( O
% O
) O
20 O
to O
60 O
mg/day O
( O
N=164 O
) O
( O
% O
) O
80 O
to O
120 O
mg/day O
( O
N=167 O
) O
( O
% O
) O
All O
EPS B-OSE_Labeled_AE
events O
5 O
12 O
20 O
All O
EPS B-OSE_Labeled_AE
events O
, O
excluding O
Akathisia B-NonOSE_AE
/ O
Restlessness B-NonOSE_AE
2 O
5 O
9 O
Note O
: O
Figures O
rounded O
to O
the O
nearest O
integer O
* O
Dystonia B-OSE_Labeled_AE
includes O
adverse O
event O
terms O
: O
dystonia B-OSE_Labeled_AE
, O
oculogyric B-OSE_Labeled_AE
crisis I-OSE_Labeled_AE
, O
oromandibular B-OSE_Labeled_AE
dystonia I-OSE_Labeled_AE
, O
tongue B-OSE_Labeled_AE
spasm I-OSE_Labeled_AE
, O
torticollis B-OSE_Labeled_AE
, O
and O
trismus B-OSE_Labeled_AE
** O
Parkinsonism B-OSE_Labeled_AE
includes O
adverse O
event O
terms O
: O
bradykinesia B-OSE_Labeled_AE
, O
cogwheel B-OSE_Labeled_AE
rigidity I-OSE_Labeled_AE
, O
drooling B-OSE_Labeled_AE
, O
extrapyramidal B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
, O
glabellar B-OSE_Labeled_AE
reflex I-OSE_Labeled_AE
abnormal I-OSE_Labeled_AE
, O
hypokinesia B-OSE_Labeled_AE
, O
muscle B-OSE_Labeled_AE
rigidity I-OSE_Labeled_AE
, O
parkinsonism B-OSE_Labeled_AE
, O
psychomotor B-OSE_Labeled_AE
retardation I-OSE_Labeled_AE
, O
and O
tremor B-OSE_Labeled_AE
Akathisia B-OSE_Labeled_AE
2 O
8 O
11 O
Dystonia B-OSE_Labeled_AE
* O
0 O
0 O
2 O
Parkinsonism B-OSE_Labeled_AE
** O
2 O
5 O
8 O
Restlessness B-OSE_Labeled_AE
< O
1 O
0 O
3 O
Adjunctive O
Therapy O
with O
Lithium O
or O
Valproate O
In O
the O
short-term O
, O
placebo-controlled O
adjunctive O
therapy O
bipolar B-Not_AE_Candidate
depression I-Not_AE_Candidate
studies O
, O
for O
LATUDA-treated O
patients O
, O
the O
incidence O
of O
EPS B-OSE_Labeled_AE
, O
excluding O
akathisia B-NonOSE_AE
and O
restlessness B-NonOSE_AE
, O
was O
13.9 O
% O
versus O
8.7 O
% O
for O
placebo O
. O

The O
incidence O
of O
akathisia B-OSE_Labeled_AE
for O
LATUDA-treated O
patients O
was O
10.8 O
% O
versus O
4.8 O
% O
for O
placebo-treated O
patients O
. O

Incidence O
of O
EPS B-OSE_Labeled_AE
is O
provided O
in O
Table O
20 O
. O

Table O
20 O
: O
Incidence O
of O
EPS O
Compared O
to O
Placebo O
in O
the O
Adjunctive O
Therapy O
Bipolar O
Depression O
Studies O
Adverse O
Event O
Term O
Placebo O
( O
N=334 O
) O
( O
% O
) O
LATUDA O
20 O
to O
120 O
mg/day O
( O
N=360 O
) O
( O
% O
) O
All O
EPS B-OSE_Labeled_AE
events O
13 O
24 O
All O
EPS B-OSE_Labeled_AE
events O
, O
excluding O
Akathisia B-NonOSE_AE
/ O
Restlessness B-NonOSE_AE
9 O
14 O
Note O
: O
Figures O
rounded O
to O
the O
nearest O
integer O
* O
Dystonia B-OSE_Labeled_AE
includes O
adverse O
event O
terms O
: O
dystonia B-OSE_Labeled_AE
, O
oculogyric B-OSE_Labeled_AE
crisis I-OSE_Labeled_AE
, O
oromandibular B-OSE_Labeled_AE
dystonia I-OSE_Labeled_AE
, O
tongue B-OSE_Labeled_AE
spasm I-OSE_Labeled_AE
, O
torticollis B-OSE_Labeled_AE
, O
and O
trismus B-OSE_Labeled_AE
** O
Parkinsonism B-OSE_Labeled_AE
includes O
adverse O
event O
terms O
: O
bradykinesia B-OSE_Labeled_AE
, O
cogwheel B-OSE_Labeled_AE
rigidity I-OSE_Labeled_AE
, O
drooling B-OSE_Labeled_AE
, O
extrapyramidal B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
, O
glabellar B-OSE_Labeled_AE
reflex I-OSE_Labeled_AE
abnormal I-OSE_Labeled_AE
, O
hypokinesia B-OSE_Labeled_AE
, O
muscle B-OSE_Labeled_AE
rigidity I-OSE_Labeled_AE
, O
parkinsonism B-OSE_Labeled_AE
, O
psychomotor B-OSE_Labeled_AE
retardation I-OSE_Labeled_AE
, O
and O
tremor B-OSE_Labeled_AE
Akathisia B-OSE_Labeled_AE
5 O
11 O
Dystonia B-OSE_Labeled_AE
* O
< O
1 O
1 O
Parkinsonism B-OSE_Labeled_AE
** O
8 O
13 O
Restlessness B-OSE_Labeled_AE
< O
1 O
4 O
In O
the O
short-term O
, O
placebo-controlled O
schizophrenia B-Not_AE_Candidate
and O
bipolar B-Not_AE_Candidate
depression I-Not_AE_Candidate
studies O
, O
data O
was O
objectively O
collected O
on O
the O
Simpson O
Angus O
Rating O
Scale O
( O
SAS O
) O
for O
extrapyramidal B-OSE_Labeled_AE
symptoms I-OSE_Labeled_AE
( I-OSE_Labeled_AE
EPS I-OSE_Labeled_AE
) O
, O
the O
Barnes O
Akathisia O
Scale O
( O
BAS O
) O
for O
akathisia B-NonOSE_AE
and O
the O
Abnormal B-NonOSE_AE
Involuntary I-NonOSE_AE
Movement O
Scale O
( O
AIMS O
) O
for O
dyskinesias B-NonOSE_AE
. O

Schizophrenia O
The O
mean O
change O
from O
baseline O
for O
LATUDA-treated O
patients O
for O
the O
SAS O
, O
BAS O
and O
AIMS O
was O
comparable O
to O
placebo-treated O
patients O
, O
with O
the O
exception O
of O
the O
Barnes O
Akathisia B-NonOSE_AE
Scale O
global O
score O
( O
LATUDA O
, O
0.1 O
; O
placebo O
, O
0.0 O
) O
. O

The O
percentage O
of O
patients O
who O
shifted O
from O
normal O
to O
abnormal O
was O
greater O
in O
LATUDA-treated O
patients O
versus O
placebo O
for O
the O
BAS O
( O
LATUDA O
, O
14.4 O
% O
; O
placebo O
, O
7.1 O
% O
) O
, O
the O
SAS O
( O
LATUDA O
, O
5.0 O
% O
; O
placebo O
, O
2.3 O
% O
) O
and O
the O
AIMS O
( O
LATUDA O
, O
7.4 O
% O
; O
placebo O
, O
5.8 O
% O
) O
. O

Bipolar O
Depression O
Monotherapy O
The O
mean O
change O
from O
baseline O
for O
LATUDA-treated O
patients O
for O
the O
SAS O
, O
BAS O
and O
AIMS O
was O
comparable O
to O
placebo-treated O
patients O
. O

The O
percentage O
of O
patients O
who O
shifted O
from O
normal O
to O
abnormal O
was O
greater O
in O
LATUDA-treated O
patients O
versus O
placebo O
for O
the O
BAS O
( O
LATUDA O
, O
8.4 O
% O
; O
placebo O
, O
5.6 O
% O
) O
, O
the O
SAS O
( O
LATUDA O
, O
3.7 O
% O
; O
placebo O
, O
1.9 O
% O
) O
and O
the O
AIMS O
( O
LATUDA O
, O
3.4 O
% O
; O
placebo O
, O
1.2 O
% O
) O
. O

Adjunctive O
Therapy O
with O
Lithium O
or O
Valproate O
The O
mean O
change O
from O
baseline O
for O
LATUDA-treated O
patients O
for O
the O
SAS O
, O
BAS O
and O
AIMS O
was O
comparable O
to O
placebo-treated O
patients O
. O

The O
percentage O
of O
patients O
who O
shifted O
from O
normal O
to O
abnormal O
was O
greater O
in O
LATUDA-treated O
patients O
versus O
placebo O
for O
the O
BAS O
( O
LATUDA O
, O
8.7 O
% O
; O
placebo O
, O
2.1 O
% O
) O
, O
the O
SAS O
( O
LATUDA O
, O
2.8 O
% O
; O
placebo O
, O
2.1 O
% O
) O
and O
the O
AIMS O
( O
LATUDA O
, O
2.8 O
% O
; O
placebo O
, O
0.6 O
% O
) O
. O

Dystonia O
Class O
Effect O
: O
Symptoms O
of O
dystonia B-OSE_Labeled_AE
, O
prolonged O
abnormal B-OSE_Labeled_AE
contractions I-OSE_Labeled_AE
of I-OSE_Labeled_AE
muscle I-OSE_Labeled_AE
groups I-OSE_Labeled_AE
, O
may O
occur O
in O
susceptible O
individuals O
during O
the O
first O
few O
days O
of O
treatment O
. O

Dystonic B-NonOSE_AE
symptoms I-NonOSE_AE
include O
: O
spasm B-NonOSE_AE
of I-NonOSE_AE
the I-NonOSE_AE
neck I-NonOSE_AE
muscles I-NonOSE_AE
, O
sometimes O
progressing O
to O
tightness B-NonOSE_AE
of I-NonOSE_AE
the I-NonOSE_AE
throat I-NonOSE_AE
, O
swallowing B-NonOSE_AE
difficulty I-NonOSE_AE
, O
difficulty B-NonOSE_AE
breathing I-NonOSE_AE
, O
and/or O
protrusion B-NonOSE_AE
of I-NonOSE_AE
the O
tongue I-NonOSE_AE
. O

While O
these O
symptoms O
can O
occur O
at O
low O
doses O
, O
they O
occur O
more O
frequently O
and O
with O
greater O
severity O
with O
high O
potency O
and O
at O
higher O
doses O
of O
first-generation O
antipsychotic O
drugs O
. O

An O
elevated O
risk O
of O
acute B-NonOSE_AE
dystonia I-NonOSE_AE
is O
observed O
in O
males O
and O
younger O
age O
groups O
. O

Schizophrenia O
In O
the O
short-term O
, O
placebo-controlled O
schizophrenia B-Not_AE_Candidate
clinical O
studies O
, O
dystonia B-OSE_Labeled_AE
occurred O
in O
4.2 O
% O
of O
LATUDA-treated O
subjects O
( O
0.0 O
% O
LATUDA O
20 O
mg O
, O
3.5 O
% O
LATUDA O
40 O
mg O
, O
4.5 O
% O
LATUDA O
80 O
mg O
, O
6.5 O
% O
LATUDA O
120 O
mg O
and O
2.5 O
% O
LATUDA O
160 O
mg O
) O
compared O
to O
0.8 O
% O
of O
subjects O
receiving O
placebo O
. O

Seven O
subjects O
( O
0.5 O
% O
, O
7/1508 O
) O
discontinued O
clinical O
trials O
due O
to O
dystonic O
events O
- O
four O
were O
receiving O
LATUDA O
80 O
mg/day O
and O
three O
were O
receiving O
LATUDA O
120 O
mg/day O
. O

Bipolar O
Depression O
Monotherapy O
In O
the O
short-term O
, O
flexible-dose O
, O
placebo-controlled O
monotherapy O
bipolar B-Not_AE_Candidate
depression I-Not_AE_Candidate
study O
, O
dystonia B-OSE_Labeled_AE
occurred O
in O
0.9 O
% O
of O
LATUDA-treated O
subjects O
( O
0.0 O
% O
and O
1.8 O
% O
for O
LATUDA O
20 O
to O
60 O
mg/day O
and O
LATUDA O
80 O
to O
120 O
mg/day O
, O
respectively O
) O
compared O
to O
0.0 O
% O
of O
subjects O
receiving O
placebo O
. O

No O
subject O
discontinued O
the O
clinical O
study O
due O
to O
dystonic B-NonOSE_AE
events I-NonOSE_AE
. O

Adjunctive O
Therapy O
with O
Lithium O
or O
Valproate O
In O
the O
short-term O
, O
flexible-dose O
, O
placebo-controlled O
adjunctive O
therapy O
bipolar B-Not_AE_Candidate
depression I-Not_AE_Candidate
studies O
, O
dystonia B-OSE_Labeled_AE
occurred O
in O
1.1 O
% O
of O
LATUDA-treated O
subjects O
( O
20 O
to O
120 O
mg O
) O
compared O
to O
0.6 O
% O
of O
subjects O
receiving O
placebo O
. O

No O
subject O
discontinued O
the O
clinical O
study O
due O
to O
dystonic B-NonOSE_AE
events I-NonOSE_AE
. O

Other O
Adverse O
Reactions O
Observed O
During O
the O
Premarketing O
Evaluation O
of O
LATUDA O
Following O
is O
a O
list O
of O
adverse O
reactions O
reported O
by O
patients O
treated O
with O
LATUDA O
at O
multiple O
doses O
of O
> O
= O
20 O
mg O
once O
daily O
within O
the O
premarketing O
database O
of O
2905 O
patients O
with O
schizophrenia B-Not_AE_Candidate
. O

The O
reactions O
listed O
are O
those O
that O
could O
be O
of O
clinical O
importance O
, O
as O
well O
as O
reactions O
that O
are O
plausibly O
drug-related O
on O
pharmacologic O
or O
other O
grounds O
. O

Reactions O
listed O
in O
Table O
15 O
or O
those O
that O
appear O
elsewhere O
in O
the O
LATUDA O
label O
are O
not O
included O
. O

Although O
the O
reactions O
reported O
occurred O
during O
treatment O
with O
LATUDA O
, O
they O
were O
not O
necessarily O
caused O
by O
it O
. O

Reactions O
are O
further O
categorized O
by O
organ O
class O
and O
listed O
in O
order O
of O
decreasing O
frequency O
according O
to O
the O
following O
definitions O
: O
those O
occurring O
in O
at O
least O
1/100 O
patients O
( O
frequent O
) O
( O
only O
those O
not O
already O
listed O
in O
the O
tabulated O
results O
from O
placebo-controlled O
studies O
appear O
in O
this O
listing O
) O
; O
those O
occurring O
in O
1/100 O
to O
1/1000 O
patients O
( O
infrequent O
) O
; O
and O
those O
occurring O
in O
fewer O
than O
1/1000 O
patients O
( O
rare O
) O
. O

Blood B-NonOSE_AE
and I-NonOSE_AE
Lymphatic I-NonOSE_AE
System I-NonOSE_AE
Disorders I-NonOSE_AE
: O
Infrequent O
: O
anemia B-OSE_Labeled_AE
Cardiac B-NonOSE_AE
Disorders I-NonOSE_AE
: O
Frequent O
: O
tachycardia B-OSE_Labeled_AE
; O
Infrequent O
: O
AV B-OSE_Labeled_AE
block I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
st I-OSE_Labeled_AE
degree I-OSE_Labeled_AE
, O
angina B-OSE_Labeled_AE
pectoris I-OSE_Labeled_AE
, O
bradycardia B-OSE_Labeled_AE
Ear B-NonOSE_AE
and I-NonOSE_AE
Labyrinth I-NonOSE_AE
Disorders I-NonOSE_AE
: O
Infrequent O
: O
vertigo B-OSE_Labeled_AE
Eye B-NonOSE_AE
Disorders I-NonOSE_AE
: O
Frequent O
: O
blurred B-OSE_Labeled_AE
vision I-OSE_Labeled_AE
Gastrointestinal B-NonOSE_AE
Disorders I-NonOSE_AE
: O
Frequent O
: O
abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
diarrhea B-OSE_Labeled_AE
; O
Infrequent O
: O
gastritis B-OSE_Labeled_AE
General B-NonOSE_AE
Disorders I-NonOSE_AE
and I-NonOSE_AE
Administrative I-NonOSE_AE
Site I-NonOSE_AE
Conditions I-NonOSE_AE
: O
Rare O
: O
sudden B-OSE_Labeled_AE
death I-OSE_Labeled_AE
Investigations B-NonOSE_AE
: O
Frequent O
: O
CPK B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
Metabolism B-NonOSE_AE
and I-NonOSE_AE
Nutritional I-NonOSE_AE
System I-NonOSE_AE
Disorders I-NonOSE_AE
: O
Frequent O
: O
decreased B-OSE_Labeled_AE
appetite I-OSE_Labeled_AE
Musculoskeletal B-NonOSE_AE
and I-NonOSE_AE
Connective I-NonOSE_AE
Tissue I-NonOSE_AE
Disorders I-NonOSE_AE
: O
Rare O
: O
rhabdomyolysis B-OSE_Labeled_AE
Nervous B-NonOSE_AE
System I-NonOSE_AE
Disorders I-NonOSE_AE
: O
Infrequent O
: O
cerebrovascular B-OSE_Labeled_AE
accident I-OSE_Labeled_AE
, O
dysarthria B-OSE_Labeled_AE
Psychiatric B-NonOSE_AE
Disorders I-NonOSE_AE
: O
Infrequent O
: O
abnormal B-OSE_Labeled_AE
dreams I-OSE_Labeled_AE
, O
panic B-OSE_Labeled_AE
attack I-OSE_Labeled_AE
, O
sleep B-OSE_Labeled_AE
disorder I-OSE_Labeled_AE
Renal B-NonOSE_AE
and I-NonOSE_AE
Urinary I-NonOSE_AE
Disorders I-NonOSE_AE
: O
Infrequent O
: O
dysuria B-OSE_Labeled_AE
; O
Rare O
: O
renal B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
Reproductive B-NonOSE_AE
System I-NonOSE_AE
and I-NonOSE_AE
Breast I-NonOSE_AE
Disorders I-NonOSE_AE
: O
Infrequent O
: O
amenorrhea B-OSE_Labeled_AE
, O
dysmenorrhea B-OSE_Labeled_AE
; O
Rare O
: O
breast B-OSE_Labeled_AE
enlargement I-OSE_Labeled_AE
, O
breast B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
galactorrhea B-OSE_Labeled_AE
, O
erectile B-OSE_Labeled_AE
dysfunction I-OSE_Labeled_AE
Skin B-NonOSE_AE
and I-NonOSE_AE
Subcutaneous I-NonOSE_AE
Tissue I-NonOSE_AE
Disorders I-NonOSE_AE
: O
Frequent O
: O
rash B-OSE_Labeled_AE
, O
pruritus B-OSE_Labeled_AE
; O
Rare O
: O
angioedema B-OSE_Labeled_AE
Vascular B-NonOSE_AE
Disorders I-NonOSE_AE
: O
Frequent O
: O
hypertension B-OSE_Labeled_AE
Clinical O
Laboratory O
Changes O
Schizophrenia O
Serum O
Creatinine O
: O
In O
short-term O
, O
placebo-controlled O
trials O
, O
the O
mean B-OSE_Labeled_AE
change I-OSE_Labeled_AE
from I-OSE_Labeled_AE
Baseline I-OSE_Labeled_AE
in I-OSE_Labeled_AE
serum I-OSE_Labeled_AE
creatinine I-OSE_Labeled_AE
was O
+0.05 O
mg/dL O
for O
LATUDA-treated O
patients O
compared O
to O
+0.02 O
mg/dL O
for O
placebo-treated O
patients O
. O

A O
creatinine B-OSE_Labeled_AE
shift O
from O
normal O
to O
high I-OSE_Labeled_AE
occurred O
in O
3.0 O
% O
( O
43/1453 O
) O
of O
LATUDA-treated O
patients O
and O
1.6 O
% O
( O
11/681 O
) O
on O
placebo O
. O

The O
threshold O
for O
high B-NonOSE_AE
creatinine I-NonOSE_AE
value O
varied O
from O
> O
0.79 O
to O
> O
1.3 O
mg/dL O
based O
on O
the O
centralized O
laboratory O
definition O
for O
each O
study O
( O
Table O
21 O
) O
. O

Table O
21 O
: O
Serum O
Creatinine O
Shifts O
from O
Normal O
at O
Baseline O
to O
High O
at O
Study O
End-Point O
in O
Schizophrenia O
Studies O
Laboratory O
Parameter O
Placebo O
( O
N=708 O
) O
LATUDA O
20mg/day O
( O
N=71 O
) O
LATUDA O
40mg/day O
( O
N=487 O
) O
LATUDA O
80mg/day O
( O
N=538 O
) O
LATUDA O
120 O
mg/day O
( O
N=291 O
) O
LATUDA O
160mg/day O
( O
N=121 O
) O
Serum B-OSE_Labeled_AE
Creatinine I-OSE_Labeled_AE
Elevated I-OSE_Labeled_AE
2 O
% O
1 O
% O
2 O
% O
2 O
% O
5 O
% O
7 O
% O
Bipolar O
Depression O
Monotherapy O
Serum O
Creatinine O
: O
In O
the O
short-term O
, O
flexible-dose O
, O
placebo-controlled O
monotherapy O
bipolar B-Not_AE_Candidate
depression I-Not_AE_Candidate
study O
, O
the O
mean B-OSE_Labeled_AE
change I-OSE_Labeled_AE
from I-OSE_Labeled_AE
Baseline I-OSE_Labeled_AE
in I-OSE_Labeled_AE
serum I-OSE_Labeled_AE
creatinine I-OSE_Labeled_AE
was O
+0.01 O
mg/dL O
for O
LATUDA-treated O
patients O
compared O
to O
-0.02 O
mg/dL O
for O
placebo-treated O
patients O
. O

A O
creatinine B-OSE_Labeled_AE
shift O
from O
normal O
to O
high I-OSE_Labeled_AE
occurred O
in O
2.8 O
% O
( O
9/322 O
) O
of O
LATUDA-treated O
patients O
and O
0.6 O
% O
( O
1/162 O
) O
on O
placebo O
( O
Table O
22 O
) O
. O

Table O
22 O
: O
Serum O
Creatinine O
Shifts O
from O
Normal O
at O
Baseline O
to O
High O
at O
Study O
End-Point O
in O
a O
Monotherapy O
Bipolar O
Depression O
Study O
Laboratory O
Parameter O
Placebo O
( O
N=168 O
) O
LATUDA20 O
to O
60 O
mg/day O
( O
N=164 O
) O
LATUDA80 O
to O
120 O
mg/day O
( O
N=167 O
) O
Serum B-OSE_Labeled_AE
Creatinine I-OSE_Labeled_AE
Elevated I-OSE_Labeled_AE
< O
1 O
% O
2 O
% O
4 O
% O
Adjunctive O
Therapy O
with O
Lithium O
or O
Valproate O
Serum O
Creatinine O
: O
In O
short-term O
, O
placebo-controlled O
premarketing O
adjunctive O
studies O
for O
bipolar B-Not_AE_Candidate
depression I-Not_AE_Candidate
, O
the O
mean B-OSE_Labeled_AE
change I-OSE_Labeled_AE
from I-OSE_Labeled_AE
Baseline I-OSE_Labeled_AE
in I-OSE_Labeled_AE
serum I-OSE_Labeled_AE
creatinine I-OSE_Labeled_AE
was O
+0.04 O
mg/dL O
for O
LATUDA-treated O
patients O
compared O
to O
-0.01 O
mg/dL O
for O
placebo-treated O
patients O
. O

A O
creatinine B-OSE_Labeled_AE
shift O
from O
normal O
to O
high I-OSE_Labeled_AE
occurred O
in O
4.3 O
% O
( O
15/360 O
) O
of O
LATUDA-treated O
patients O
and O
1.6 O
% O
( O
5/334 O
) O
on O
placebo O
( O
Table O
23 O
) O
. O

Table O
23 O
: O
Serum O
Creatinine O
Shifts O
from O
Normal O
at O
Baseline O
to O
High O
at O
Study O
End-Point O
in O
the O
Adjunctive O
Therapy O
Bipolar B-Not_AE_Candidate
Depression I-Not_AE_Candidate
Studies O
Laboratory O
Parameter O
Placebo O
( O
N=334 O
) O
LATUDA O
20 O
to O
120 O
mg/day O
( O
N=360 O
) O
Serum B-OSE_Labeled_AE
Creatinine I-OSE_Labeled_AE
Elevated I-OSE_Labeled_AE
2 O
% O
4 O
% O

